Association between Sleep and Alzheimer’s Disease: A Bibliometric Analysis from 2003 to 2022

Tang, Ming; Wu, Li; Shen, Ziyi; Chen, Junwen; Yang, Yang; Zhang, Ming; Zhao, Peilin; Jiang, Guohui

doi:10.1159/000533700

Cited by 3 publications

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The LHA plays a critical role in maintaining the sleep-and wake cycle; approximately 25-44% of AD patients suffer from sleep-wake disturbance 44,45 . Excessive daytime sleepiness, reduction in sleep efficiency with fragmented sleep at night, a decrease in the percentage of time of NREM3 stages and REM sleep, and an increase in wake after sleep onset, indicate that the wakepromoting system gets severely affected in AD 17,18 .…”

Section: Discussionmentioning

confidence: 99%

The wake- and sleep-modulating neurons of the lateral hypothalamic area demonstrate a differential pattern of degeneration in Alzheimer’s disease

Satpati,

Pereira,

Soloviev

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Sleep-wake dysfunction is an early and common event in Alzheimers disease (AD). The lateral hypothalamic area (LHA) regulates the sleep and wake cycle through wake-promoting orexinergic and sleep-promoting melanin-concentrating hormone (MCH) neurons. These neurons share close anatomical proximity with functional reciprocity. This study investigated the pattern of neuronal loss (ORX and MCH) in the LHA in AD. Understanding the degeneration pattern of these neurons will be instrumental in designing potential therapeutics to slow down the disease progression and remediate the sleep-wake dysfunction in AD. Methods: Postmortem human brain tissue of subjects with AD (across progressive stages) and controls were examined using unbiased stereology. Neuronal counting was done using double immunohistochemistry with ORX, pTau (CP13), and MCH, pTau (CP13) labeled neurons on formalin-fixed, celloidin-embedded tissue. Results: We observed a progressive decline in orexinergic (ORX) neurons and a relative preservation of the melanin-concentrating hormone (MCH) neurons. The decline in ORX neurons was seen from BB 2 (56%, p=0.0634). By the late stage of the disease (BB 5-6), the decline in ORX neurons was 76% (p=0.0043). In contrast, the MCH neurons demonstrated an insignificant decline by BB 6 (25%, p=0.1313). Conclusions: Our data demonstrated very early substantial ORX neuronal loss in the LHA, while MCH neurons were resilient to AD pTau accumulation. Interventions capable of preventing ORX neuronal loss and inhibiting pTau accumulation in the LHA can reinstate sleep-wake dysfunction in AD and possibly prevent the progression of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

The wake- and sleep-modulating neurons of the lateral hypothalamic area demonstrate a differential pattern of degeneration in Alzheimer’s disease

Satpati,

Pereira,

Soloviev

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Sphingosine-1-phosphate in the regulation of diabetes mellitus: a scientometric study to an in‐depth review

Li,

Fan,

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetes is a significant global health issue, causing extensive morbidity and mortality, and represents a serious threat to human health. Recently, the bioactive lipid molecule Sphingosine-1-Phosphate has garnered considerable attention in the field of diabetes research. The aim of this study is to comprehensively understand the mechanisms by which Sphingosine-1-Phosphate regulates diabetes. Through comprehensive bibliometric analysis and an in-depth review of relevant studies, we investigated and summarized various mechanisms through which Sphingosine-1-Phosphate acts in prediabetes, type 1 diabetes, type 2 diabetes, and their complications (such as diabetic nephropathy, retinopathy, cardiovascular disease, neuropathy, etc.), including but not limited to regulating lipid metabolism, insulin sensitivity, and inflammatory responses. This scholarly work not only unveils new possibilities for using Sphingosine-1-Phosphate in diabetes treatment but also offers fresh insights and recommendations for future research directions to researchers.

show abstract

Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges

Safiri,

Ghaffari Jolfayi,

Fazlollahi

et al. 2024

Front. Med.

View full text Add to dashboard Cite

BackgroundAlzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired reasoning. It is the leading cause of dementia in older adults, marked by the pathological accumulation of amyloid-beta plaques and neurofibrillary tangles. These pathological changes lead to widespread neuronal damage, significantly impacting daily functioning and quality of life.ObjectiveThis comprehensive review aims to explore various aspects of Alzheimer's disease, including its epidemiology, risk factors, clinical presentation, diagnostic advancements, management strategies, caregiving challenges, and emerging therapeutic interventions.MethodsA systematic literature review was conducted across multiple electronic databases, including PubMed, MEDLINE, Cochrane Library, and Scopus, from their inception to May 2024. The search strategy incorporated a combination of keywords and Medical Subject Headings (MeSH) terms such as “Alzheimer's disease,” “epidemiology,” “risk factors,” “symptoms,” “diagnosis,” “management,” “caregiving,” “treatment,” and “novel therapies.” Boolean operators (AND, OR) were used to refine the search, ensuring a comprehensive analysis of the existing literature on Alzheimer's disease.ResultsAD is significantly influenced by genetic predispositions, such as the apolipoprotein E (APOE) ε4 allele, along with modifiable environmental factors like diet, physical activity, and cognitive engagement. Diagnostic approaches have evolved with advances in neuroimaging techniques (MRI, PET), and biomarker analysis, allowing for earlier detection and intervention. The National Institute on Aging and the Alzheimer's Association have updated diagnostic criteria to include biomarker data, enhancing early diagnosis.ConclusionThe management of AD includes pharmacological treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, which provide symptomatic relief but do not slow disease progression. Emerging therapies, including amyloid-beta and tau-targeting treatments, gene therapy, and immunotherapy, offer potential for disease modification. The critical role of caregivers is underscored, as they face considerable emotional, physical, and financial burdens. Support programs, communication strategies, and educational interventions are essential for improving caregiving outcomes. While significant advancements have been made in understanding and managing AD, ongoing research is necessary to identify new therapeutic targets and enhance diagnostic and treatment strategies. A holistic approach, integrating clinical, genetic, and environmental factors, is essential for addressing the multifaceted challenges of Alzheimer's disease and improving outcomes for both patients and caregivers.

show abstract

Association between Sleep and Alzheimer’s Disease: A Bibliometric Analysis from 2003 to 2022

Cited by 3 publications

References 67 publications

The wake- and sleep-modulating neurons of the lateral hypothalamic area demonstrate a differential pattern of degeneration in Alzheimer’s disease

The wake- and sleep-modulating neurons of the lateral hypothalamic area demonstrate a differential pattern of degeneration in Alzheimer’s disease

Sphingosine-1-phosphate in the regulation of diabetes mellitus: a scientometric study to an in‐depth review

Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges

Contact Info

Product

Resources

About